TGF-β and microvessel homeostasis

Microvascular Research

Volumn 80, Issue 1, 2010, Pages 166-173

  Walshe, Tony E ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

Capillary; Endothelial cell; Pericyte; TGF

Indexed keywords

ENDOGLIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 2; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PROSTACYCLIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL TONE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HEART INFARCTION; HUMAN; INFLAMMATION; MICROVASCULATURE; NONHUMAN; PREECLAMPSIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RENDU OSLER WEBER DISEASE; REPERFUSION INJURY; REVIEW; TIGHT JUNCTION; VASCULAR ENDOTHELIUM;

ANIMALS; HOMEOSTASIS; HUMANS; MICROVESSELS; TRANSFORMING GROWTH FACTOR BETA;

EID: 77953545108     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2010.03.003     Document Type: Review

References (104)

1. Antonelli-Orlidge A., et al. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc. Natl Acad. Sci. U.S. A. 1989, 86:4544-4548.
2. Baker A.B., et al. Endothelial cells provide feedback control for vascular remodeling through a mechanosensitive autocrine TGF-{beta} signaling pathway. Circ. Res. 2008, 103(3):289-297.
3. Bessa X., et al. Leukocyte recruitment in colon cancer: role of cell adhesion molecules, nitric oxide, and transforming growth factor beta1. Gastroenterology 2002, 122:1122-1132.
4. Bian Z.M., et al. Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells. Exp. Eye Res. 2007, 84(5):812-822.
5. Birukova A.A., et al. ALK5 and Smad4 are involved in TGF-beta1-induced pulmonary endothelial permeability. FEBS Lett. 2005, 579:4031-4037.
6. Björkerud S. Effects of transforming growth factor-beta 1 on human arterial smooth muscle cells in vitro. Arterioscler. Thromb. 1991, 11:892-902.
7. Blobe G.C., et al. Role of transforming growth factor beta in human disease. N. Engl. J. Med. 2000, 342:1350-1358.
8. Byrne C.D., et al. Increased PAI activity and PAI-1 antigen occurring with an oral fat load: associations with PAI-1 genotype and plasma active TGF-beta levels. Atherosclerosis 1998, 140:45-53.
9. Camici P.G., Crea F. Coronary microvascular dysfunction. N. Engl. J. Med. 2007, 356:830-840.
10. Carvalho R.L.C., et al. Compensatory signalling induced in the yolk sac vasculature by deletion of TGFbeta receptors in mice. J. Cell Sci. 2007, 120:4269-4277.
11. Castañares C., et al. Transforming growth factor-beta receptor requirements for the induction of the endothelin-1 gene. Exp. Biol. Med. (Maywood) 2006, 231:700-703.
12. Castañares C., et al. Signaling by ALK5 mediates TGF-beta-induced ET-1 expression in endothelial cells: a role for migration and proliferation. J. Cell Sci. 2007, 120:1256-1266.
13. Chaudhry S.S., et al. Fibrillin-1 regulates the bioavailability of TGFbeta1. J. Cell Biol. 2007, 176:355-367.
14. Chen J., et al. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat. Med. 2005, 11:1188-1196.
15. Chen Y., et al. Soluble endoglin modulates aberrant cerebral vascular remodeling. Ann. Neurol. 2009, 66:19-27.
16. Choi M.E., Ballermann B.J. Inhibition of capillary morphogenesis and associated apoptosis by dominant negative mutant transforming growth factor-beta receptors. J. Biol. Chem. 1995, 270:21144-21150.
17. Cipollone F., et al. Increased expression of transforming growth factor-beta1 as a stabilizing factor in human atherosclerotic plaques. Stroke 2004, 35:2253-2257.
18. Clifford R.L., et al. Novel regulation of vascular endothelial growth factor-A (VEGF-A) by transforming growth factor (beta)1: requirement for Smads, (beta)-catenin, and GSK3(beta). J. Biol. Chem. 2008, 283:35337-35353.
19. Conley B.A., et al. Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis 2000, 153:323-335.
20. Cruz-Gonzalez I., et al. Identification of serum endoglin as a novel prognostic marker after acute myocardial infarction. J. Cell. Mol. Med. 2008, 12(3):955-961.
21. Darland D.C., et al. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev. Biol. 2003, 264:275-288.
22. Dell'Omo G., et al. Lack of association between TGF-beta-1 genotypes and microalbuminuria in essential hypertensive men. Nephrol. Dial. Transplant. 2009, 24:1864-1869.
23. Derhaschnig U., et al. Increased levels of transforming growth factor-beta1 in essential hypertension. Am. J. Hypertens. 2002, 15:207-211.
24. Docherty N.G., et al. Endoglin regulates renal ischaemia-reperfusion injury. Nephrol. Dial. Transplant. 2006, 21:2106-2119.
25. Dohgu S., et al. Brain pericytes contribute to the induction and up-regulation of blood-brain barrier functions through transforming growth factor-beta production. Brain Res. 2005, 1038:208-215.
26. Dragomir E., et al. High glucose conditions induce upregulation of fractalkine and monocyte chemotactic protein-1 in human smooth muscle cells. Thromb. Haemost. 2008, 100:1155-1165.
27. Dünker N., Krieglstein K. Targeted mutations of transforming growth factor-beta genes reveal important roles in mouse development and adult homeostasis. Eur. J. Biochem. 2000, 267:6982-6988.
28. Dziadzio M., et al. Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatology (Oxford) 2005, 44:1518-1524.
29. Farkas L., et al. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J. Clin. Invest. 2009, 119:1298-1311.
30. Fernandez-L A., et al. Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells. Thromb. Haemost. 2007, 97:254-262.
31. Flaumenhaft R., et al. Role of the latent TGF-beta binding protein in the activation of latent TGF-beta by co-cultures of endothelial and smooth muscle cells. J. Cell Biol. 1993, 120:995-1002.
32. Frutkin A.D., et al. TGF-{beta}1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 2009, 29(9):1251-1271.
33. Fu Z., et al. Milk fat globule protein epidermal growth factor-8: a pivotal relay element within the angiotensin II and monocyte chemoattractant protein-1 signaling cascade mediating vascular smooth muscle cells invasion. Circ. Res. 2009, 104:1337-1346.
34. Gamble J.R., et al. Transforming growth factor-beta inhibits E-selectin expression on human endothelial cells. J. Immunol. 1993, 150:4494-4503.
35. Gamble J.R., Vadas M.A. Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-beta. Science 1988, 242:97-99.
36. Gohongi T., et al. Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: involvement of transforming growth factor beta1. Nat. Med. 1999, 5:1203-1208.
37. Goumans M.J., et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol. Cell. 2003, 12:817-828.
38. Grainger D.J., et al. Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions. J. Cell Sci. 2000, 113(Pt 13):2355-2361.
39. Guttmacher A.E., et al. Hereditary hemorrhagic telangiectasia. N. Engl. J. Med. 1995, 333:918-924.
40. Hata Y., et al. Retinal expression, regulation, and functional bioactivity of prostacyclin-stimulating factor. J. Clin. Invest. 2000, 106:541-550.
41. Hirschi K.K., et al. PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J. Cell Biol. 1998, 141:805-814.
42. Ito C., et al. TGF-beta inhibits vascular sprouting through TGF-beta type I receptor in the mouse embryonic aorta. Tohoku J. Exp. Med. 2009, 218:63-71.
43. Jackson B.A., et al. Effects of transforming growth factor beta and interleukin-1 beta on expression of cyclooxygenase 1 and 2 and phospholipase A2 mRNA in lung fibroblasts and endothelial cells in culture. Biochem. Biophys. Res. Commun. 1993, 197:1465-1474.
44. Jeon S.H., et al. Mechanisms underlying TGF-beta1-induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesis. J. Leukoc. Biol. 2007, 81:557-566.
45. Jerkic M., et al. Reduced angiogenic responses in adult endoglin heterozygous mice. Cardiovasc. Res. 2006, 69:845-854.
46. Junker U., et al. Elevated plasma TGF-beta1 in renal diseases: cause or consequence?. Cytokine 2000, 12:1084-1091.
47. Kano M.R., et al. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci. 2008.
48. Kobayashi K., et al. Targeted disruption of TGF-beta-Smad3 signaling leads to enhanced neointimal hyperplasia with diminished matrix deposition in response to vascular injury. Circ. Res. 2005, 96:904-912.
49. Koch W., et al. Association of transforming growth factor-beta1 gene polymorphisms with myocardial infarction in patients with angiographically proven coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1114-1119.
50. Kojima S., et al. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J. Cell Biol. 1991, 113:1439-1445.
51. Kose N., et al. Altered expression of basement membrane-related molecules in rat brain pericyte, endothelial, and astrocyte cell lines after transforming growth factor-beta1 treatment. Drug Metab. Pharmacokinet. 2007, 22:255-266.
52. Kulkarni A.B., et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl Acad. Sci. U.S.A. 1993, 90:770-774.
53. Lan Y., et al. Essential role of endothelial Smad4 in vascular remodeling and integrity. Mol. Cell. Biol. 2007, 27:7683-7692.
54. Lebrin F., et al. TGF-beta receptor function in the endothelium. Cardiovasc. Res. 2005, 65:599-608.
55. Lee N.Y., et al. Casein kinase 2{beta} as a novel enhancer of activin-like receptor-1 signaling. FASEB J. 2009, 23(11):3712-3721.
56. Lee N.Y., et al. Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. J. Biol. Chem. 2008, 283:32527-32533.
57. Lee Y.H., et al. Transforming growth factor-beta1 effects on endothelial monolayer permeability involve focal adhesion kinase/Src. Am. J. Respir. Cell Mol. Biol. 2007, 37:485-493.
58. Lefer A.M., et al. Mechanism of the cardioprotective effect of transforming growth factor beta 1 in feline myocardial ischemia and reperfusion. Proc. Natl Acad. Sci. U.S.A. 1993, 90:1018-1022.
59. Letarte M., et al. Reduced endothelial secretion and plasma levels of transforming growth factor-beta1 in patients with hereditary hemorrhagic telangiectasia type 1. Cardiovasc. Res. 2005, 68:155-164.
60. Levine R.J., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 2006, 355:992-1005.
61. Long L., et al. Altered bone morphogenetic protein and transforming growth factor-{beta} signaling in rat models of pulmonary hypertension. potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 2009, 119(4):556-567.
62. Lu Q. Transforming growth factor-beta1 protects against pulmonary artery endothelial cell apoptosis via ALK5. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 295:L123-L133.
63. Lu Q., et al. Transforming growth factor-{beta}1 causes pulmonary microvascular endothelial cell apoptosis via ALK5. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 296:L825-L838.
64. Ma J., et al. MCP-1 mediates TGF-beta-induced angiogenesis by stimulating vascular smooth muscle cell migration. Blood 2007, 109:987-994.
65. Maharaj A.S., et al. Vascular endothelial growth factor localization in the adult. Am. J. Pathol. 2006, 168:639-648.
66. McCaffrey T.A., et al. The expression of TGF-beta receptors in human atherosclerosis: evidence for acquired resistance to apoptosis due to receptor imbalance. J. Mol. Cell. Cardiol. 1999, 31:1627-1642.
67. Merwin J.R., et al. Transforming growth factor beta 1 modulates extracellular matrix organization and cell-cell junctional complex formation during in vitro angiogenesis. J. Cell. Physiol. 1990, 142:117-128.
68. Meyer-Kirchrath J., et al. Gene expression profile of the Gs-coupled prostacyclin receptor in human vascular smooth muscle cells. Biochem. Pharmacol. 2004, 67:757-765.
69. Nakamura K., et al. Altered nano/micro-order elasticity of pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Int. J. Cardiol. 2010, 140(1):102-107.
70. Negishi M., et al. Upregulatory expression of furin and transforming growth factor-beta by fluid shear stress in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2001, 21:785-790.
71. Neubauer K., et al. Transforming growth factor-beta1 stimulates the synthesis of basement membrane proteins laminin, collagen type IV and entactin in rat liver sinusoidal endothelial cells. J. Hepatol. 1999, 31:692-702.
72. Nosaka S., et al. Antithrombotic effects of endocardial endothelial cells-comparison with coronary artery endothelial cells. Prostaglandins 1997, 53:305-319.
73. Ohno M., et al. Fluid shear stress induces endothelial transforming growth factor beta-1 transcription and production. Modulation by potassium channel blockade. J. Clin. Invest. 1995, 95:1363-1369.
74. Os I., et al. Transforming growth factor (TGF)-beta1 inversely related to vascular cell adhesion molecule-1 in postmenopausal women with coronary artery disease. A possible mechanism for the putative cardioprotective role of TGF-beta1?. J. Intern. Med. 2002, 251:223-227.
75. Park S.K., et al. TGF-beta(1) down-regulates inflammatory cytokine-induced VCAM-1 expression in cultured human glomerular endothelial cells. Nephrol. Dial. Transplant. 2000, 15:596-604.
76. Pepper M.S., et al. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis. Exp. Cell Res. 1993, 204:356-363.
77. Ristimaki A., et al. Effect of growth factors on human vascular endothelial cell prostacyclin production. Arteriosclerosis 1990, 10:653-657.
78. Rudini N., et al. VE-cadherin is a critical endothelial regulator of TGF-beta signalling. EMBO J. 2008, 27:993-1004.
79. Saint-Geniez M., et al. Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors. PLoS ONE 2008, 3:e3554.
80. Sankar S., et al. Modulation of transforming growth factor beta receptor levels on microvascular endothelial cells during in vitro angiogenesis. J. Clin. Invest. 1996, 97:1436-1446.
81. Santibanez J., et al. Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling. J. Cell. Physiol. 2007, 210:456-468.
82. Sato Y., et al. Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J. Cell Biol. 1990, 111:757-763.
83. Saura M., et al. Nitric oxide regulates transforming growth factor-beta signaling in endothelial cells. Circ. Res. 2005, 97:1115-1123.
84. Schepers A., et al. Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2063-2069.
85. Schwartz E.A., et al. Transforming growth factor-beta receptors localize to caveolae and regulate endothelial nitric oxide synthase in normal human endothelial cells. Biochem. J. 2005, 390:199-206.
86. Shull M.M., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992, 359:693-699.
87. Tatti O., et al. MT1-MMP releases latent TGF-beta1 from endothelial cell extracellular matrix via proteolytic processing of LTBP-1. Exp. Cell Res. 2008, 314(13):2501-2514.
88. Thomas M., et al. Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. Am. J. Pathol. 2009, 174:380-389.
89. Tokuda H., et al. Involvement of MAP kinases in TGF-beta-stimulated vascular endothelial growth factor synthesis in osteoblasts. Arch. Biochem. Biophys. 2003, 415:117-125.
90. Tong X.K., Hamel E. Transforming growth factor-beta 1 impairs endothelin-1-mediated contraction of brain vessels by inducing mitogen-activated protein (MAP) kinase phosphatase-1 and inhibiting p38 MAP kinase. Mol. Pharmacol. 2007, 72:1476-1483.
91. Toporsian M., et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ. Res. 2005, 96:684-692.
92. Torsney E., et al. Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality. Circulation 2003, 107:1653-1657.
93. Van Laake L., et al. Endoglin has a crucial role in blood cell-mediated vascular repair. Circulation 2006, 114:2288-2297.
94. van Royen N., et al. Exogenous application of transforming growth factor beta 1 stimulates arteriogenesis in the peripheral circulation. FASEB J. 2002, 16:432-434.
95. Venkatesha S., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 2006, 12:642-649.
96. Wagner D.D., Frenette P.S. The vessel wall and its interactions. Blood 2008, 111:5271-5281.
97. Walshe T., et al. TGF-beta is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature. PLoS ONE 2009, 4:e5149.
98. Walshe T.E., et al. Inhibition of VEGF or TGF-{beta} signaling activates endothelium and increases leukocyte rolling. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1185-1192.
99. Walshe T.E., et al. TGF-beta is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature. PLoS ONE 2009, 4:e5149.
100. Yang Z., et al. Absence of integrin-mediated TGFbeta1 activation in vivo recapitulates the phenotype of TGFbeta1-null mice. J. Cell Biol. 2007, 176:787-793.
101. Yao Y., et al. Activin-like kinase receptor 1 (ALK1) in atherosclerotic lesions and vascular mesenchymal cells. Cardiovasc. Res. 2007, 74:279-289.
102. Young B.C., et al. Pathogenesis of preeclampsia. Annu. Rev. Pathol. Mech. Dis. 2010, 5:173-192.
103. Young G.D., Murphy-Ullrich J.E. The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-beta complex. J. Biol. Chem. 2004, 279:47633-47642.
104. Zhang F., et al. Transforming growth factor-beta promotes recruitment of bone marrow cells and bone marrow-derived mesenchymal stem cells through stimulation of MCP-1 production in vascular smooth muscle cells. J. Biol. Chem. 2009, 284:17564-17574.